An Ascending Multiple Dose Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of GSI-953 Administered Orally To Healthy Elderly Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2011
At a glance
- Drugs Begacestat (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics; Pharmacokinetics
- 19 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 09 Jul 2008 Status changed from recruiting to in progress as reported by ClinicalTrials.gov.